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Abstract
Background: Phenotypically similar diseases have been found to be caused by functionally related genes, suggesting a
modular organization of the genetic landscape of human diseases that mirrors the modularity observed in biological
interaction networks. Protein complexes, as molecular machines that integrate multiple gene products to perform biological
functions, express the underlying modular organization of protein-protein interaction networks. As such, protein complexes
can be useful for interrogating the networks of phenome and interactome to elucidate gene-phenotype associations of
diseases.
Methodology/Principal Findings: We proposed a technique called RWPCN (Random Walker on Protein Complex Network)
for predicting and prioritizing disease genes. The basis of RWPCN is a protein complex network constructed using existing
human protein complexes and protein interaction network. To prioritize candidate disease genes for the query disease
phenotypes, we compute the associations between the protein complexes and the query phenotypes in their respective
protein complex and phenotype networks. We tested RWPCN on predicting gene-phenotype associations using leave-one-
out cross-validation; our method was observed to outperform existing approaches. We also applied RWPCN to predict novel
disease genes for two representative diseases, namely, Breast Cancer and Diabetes.
Conclusions/Significance: Guilt-by-association prediction and prioritization of disease genes can be enhanced by fully
exploiting the underlying modular organizations of both the disease phenome and the protein interactome. Our RWPCN
uses a novel protein complex network as a basis for interrogating the human phenome-interactome network. As the protein
complex network can capture the underlying modularity in the biological interaction networks better than simple protein
interaction networks, RWPCN was found to be able to detect and prioritize disease genes better than traditional approaches
that used only protein-phenotype associations.
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Introduction
Uncovering the associations between the genetic diseases and
their causative genes is a fundamental objective of human genetics
[1]. However, despite the recent genomic revolution, it still
remains a daunting challenge because of the pleiotropy of genes,
the limited number of phenotype-gene associations, the genetic
heterogeneity of diseases, as well as other complications [2,3].
In recent years, there has been an increase in the number of
genes confirmed as causative genes to diseases [4]. Such
information can be exploited by computational methods to predict
or prioritize new disease-gene associations. A common approach is
to measure the similarities between the candidate genes and the
known disease causative genes based on biological evidences of
these genes such as protein sequence information [5], gene
expression profiles [6], and even literature descriptions [7].
Candidate genes that share high similarities with the known
disease causative genes can then be ranked as the putative disease
genes to be validated by biologists or clinicians. However, these
approaches are limited by the quality and completeness of the
biological evidences. They are also not very useful for inferring
causative genes for new diseases, for it will depend not only on the
accuracy of the biological similarities of the genes being compared,
but also on the ability to categorize similar diseases correctly.
Given that different diseases encompass different but sometime
overlapping collections of clinical phenotypes, a more viable
approach would be to link or prioritize the candidate genes based
on the clinical manifestations of the diseases, that is, to identify
gene-phenotype associations instead of gene-disease associations
directly.
Recent studies have revealed that similar phenotypes are often
caused by functionally related genes [8,9], and genes associated
with similar disorders have been shown to demonstrate higher
probability of physical interactions between their gene products
[10,11]. This suggests a guilt-by-association prediction and
prioritization of disease genes by interrogating the networks of
phenome and interactome for correlations that elucidate gene-
phenotype associations of diseases. A graphical map of the
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node, and then linking the highly similar phenotypes (e.g. based on
the similarity in their corresponding OMIM records or the domain
knowledge form clinicians). On the other hand, a graphical map of
the interactome can be constructed more directly by considering
each individual protein as a node, and the existence of an
experimentally detected protein-protein interaction (PPI) as a link
between the two corresponding nodes. The recent advent in high-
throughput methods for detecting PPIs en masse (e.g. yeast-two-
hybrid, co-immunoprecipitation-coupled mass spectroscopy) has
enabled the construction of PPI networks on a genomic scale. With
the two networks, we can then infer gene-phenotype associations
by computing the closeness between the candidate genes and
known disease genes based on network topological properties
[3,12–14]. For example, Wu et al. [15] built a regression model
measuring the correlation between phenotype similarities and
gene closeness in the PPI network for prioritizing candidate disease
genes based on the correlation scores. However, Wu’s method is
limited by the consideration of only small localized regions in both
the protein interaction network and phenotype network. To
address this issue, Vanunu and Sharan [16] designed a global
network-based method by formulating constraints on the genes’
score function that related to its smoothness over the network.
Most recently, Li and Patra [3] proposed a new method to
prioritize disease genes by extending the random walk with restart
algorithm on a heterogeneous network constructed by connecting
the gene network (i.e. protein interaction network) and the
phenotype network using known phenotype-gene relationships.
The observation that phenotypically similar diseases are often
caused by functionally related genes also suggests a modular
organization of the genetic landscape of human diseases. Many
specific examples have shown that individual genes that cause a
given phenotype tend to be linked at the biological levels as
components of a multi-protein complex [10,11]. In other words,
the causative genes for the same or phenotypically similar diseases
are likely to reside in the same biological module. Protein
complexes, as molecular machines that integrate multiple gene
products to perform biological functions, are direct manifestations
of biological modules. They are also detected as tightly linked
substructures in PPI networks [17], reflecting the modularity of
biological networks graphically. As such, protein complexes can be
a useful basis for interrogating the networks of phenome and
interactome to elucidate gene-phenotype associations of diseases.
Both the Vanunu and Li methods mentioned above did not
make use of protein complexes to aid in their inference of gene-
phenotype associations. In an earlier work, Lage et al. [18] made
use of protein complexes for prioritization of disease genes via
phenotypic weighting of protein complexes linked to human
diseases. However, they did not use actual protein complexes but
simply assembled neighboring proteins as complexes (consist of a
protein and all their direct interaction partners). They also ignored
the biological relationships between the protein complexes. For
example, it has been reported that if two protein complexes share
a number of common proteins or have densely physical
interactions between them, the mutations of genes in one protein
complex could lead to same or similar phenotypes of the other
protein complex [11]. As such, incorporating quality-controlled
protein complexes and accounting for their relationships are both
essential for accurate disease gene prediction. In this work, we
therefore propose to construct a novel protein complex network,
where nodes are individual complexes and the interactions
between two complexes are measured by the connection strengths
between them, as a basis for interrogating the phenome-
interactome networks for disease gene prioritization. We devise a
novel globally network-based technique called RWPCN (Random
Walker on Protein Complex Network) for elucidating novel gene-
phenotype relationships on such a network.
Our proposed method is different from the existing methods as
our network propagation algorithm is operated at the complex-
level instead of the protein level. We used reliable human protein
complexes from the Comprehensive Resource of Mammalian
protein complexes (CORUM) [19] since the protein complexes
were curated from the biological literatures. To our best
knowledge, this is the first attempt to capture and exploit the
biological modularity of the protein complexes and their
relationships in an explicit way. Our experimental results
showed that such an effort was indeed worth the while, for our
proposed algorithm was able to discover gene-disease associa-
tions more effectively as compared with existing state-of-the-art
methods.
Materials and Methods
In this section, we will first describe the experimental data we
have used. Then, we will introduce the overall network structure
for our RWPCN algorithm, including the phenotype network,
protein complex network, protein interaction network, as well as
gene-phenotype associations. Finally, we describe the construction
of the phenotype network and protein complex network. With
these, we then present our RWPCN algorithm for prioritizing
disease-related genes.
Data Set
Protein interaction data. Human PPI data were
downloaded from the Human Protein Reference database
(HPRD) [20] database which has 34364 interactions among
8919 human proteins/genes. We filtered out the proteins with only
self-interactions, resulting in 8756 human proteins.
Protein complex data. Human protein complexes data were
downloaded from the Comprehensive Resource of Mammalian
protein complexes (CORUM) database [19]. The CORUM
database is a collection of experimentally verified mammalian
protein complexes and these protein complexes are manually
extracted from literature. The records of CORUM protein
complexes are generated by different kinds of experiments, such
as coimmunoprecipitation, cosedimentation, and ion exchange chromatography.
We only considered those human protein complexes that include
at least one gene in HPRD human protein interaction data. This
resulted in 379 human protein complexes with an average size (the
average number of proteins) of 3.83. This set of protein complexes
contains a total of 918 human genes, covering 10.5% of human
genes in our PPI network. Note that we have also filtered out giant
complexes if they covered a number of smaller complexes.
Recall that we also view those proteins which are not included
in any CORUM protein complexes as individual protein
complexes. There were 7838 of these, and 3964 of these individual
protein complexes directly interact with CORUM complexes in
our resulting protein complex network.
Gene-phenotype associations. Gene-phenotype associa-
tions are assembled from the OMIM database [4], using
BIOMART [21]. In our experiments, we exploited an old
version of gene-phenotype association data used in previous
studies [3,15] to facilitate comparisons. 1428 known gene-
phenotype associations were extracted, spanning 1126 disease
phenotypes and 937 causative genes. In addition, we also collected
a new version of gene-phenotype relationships from BIOMART
[22], which contained 1614 links, with 1266 disease phenotypes
and 1034 causative genes.
Disease Gene Prediction on Protein Complex Network
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Figure 1 depicts the overall network structure used in RWPCN.
It consists of three levels of networks, namely, the phenotype
network (top), protein complex network (middle), and the protein
interaction network (bottom). In the phenotype network at the top
level, we connect phenotypes if their similarity scores are bigger
than a pre-defined threshold. The similarity scores are also used to
weight the links. In the Figure, the links are marked with purple
lines, where the thicker lines denote higher phenotypic similarities.
The protein complex network in the middle layer is where
phenotypically-related protein complexes areconnected.Withinthe
protein complex networks,the links aremarkedwithgraylines, with
the thicker lines indicating stronger linkage strengths between the
two corresponding protein complexes. We will describe how to
compute the protein complexes’ linkage strengths later. The links
between the phenotypes and complexes capture the known gene-
phenotype associations, denoted by dashed red lines.
At the bottom level is the PPI network. Two proteins are
connected if they were reported to be interacting to each other.
Across the networks, each protein complex in the middle level links
with all its component proteins (yellow nodes) in the PPI network.
Given a query disease phenotype (a query node in the top level),
our objective is to predict disease genes for this phenotype in the
bottom level PPI network, guided by the protein complex
relationships in the middle level. Our proposed RWPCN
algorithm will traverse between the three networks and exploit
the structural relationships accordingly.
Constructing Phenotype Network
Biologists already have a detailed knowledge of the phenotypes
that are associated with each other. These phenotype associations
have been used to prioritize candidate disease genes as well as to
discover functional relations between genes and proteins [23].
As in the method by van Driel [23], we construct the phenotype
network by applying a text-mining approach to evaluate the
similarity among OMIM phenotypes using Medical Subject
Headings (MeSH) controlled vocabulary as standardized pheno-
typic feature terms. A phenotype ptMPT (PT is the set of all the
phenotypes) is represented as a feature vector pt=(x1, x2,…, xl)
where each dimension represents a vocabulary of Medical Subject
Headings. A dimension i (1,=i,=l) in the feature vector pt
represents a MeSH concept which provides a standardized way to
retrieve information to refer to the concept. Each feature value xi is
the weight of i
th MeSH concept, which is determined by the
concept relevance and document frequency in [23].
Given two pti=(xi1, xi2,…, xil), ptj=(yj1, yj2,…, yjl), we measure
the phenotypic similarity between two vectors by the cosine
similarity between the normalized vectors, i.e.,
sim(pti,ptj)~
P l
k~1
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ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
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Figure 1. Illustration of the overall network structure in RWPCN. Top level phenotype network connects the phenotypes and query
phenotype if their phenotypic similarity scores are bigger enough. The similarity scores are used to weight the links (the links are marked with purple
lines, where the thicker lines denote higher phenotypic similarities). The middle level of the network is protein complex network where phenotype-
related protein complexes are connected. The links between two protein complexes marked with gray lines, with the thicker lines indicate the strong
linkage strength. On the other hand, the links between the phenotypes and complexes indicate the known gene-phenotype associations, denoted by
dashed blue lines. The bottom level of the network is the protein interaction network where each protein complex in the middle level links with all its
component proteins (yellow nodes).
doi:10.1371/journal.pone.0021502.g001
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believed to be uninformative and noisy while those in [0.6, 1] are
considered to be reliable [23]. Therefore, we re-compute the
phenotypic similarity between pti and ptj using a logical function
L(sim(pti,ptj))~ 1
1ze
(c sim(pti,ptj)zd) used in [24]. We used the
default values recommended in [24] for the parameters c and d,
namely c=-15 and d=log(9999) respectively.
We construct our phenotype network using k-NN model (k-
Nearest Neighbor). That is, for each phenotype pti, we compute its
top k most similar phenotypic neighbors (i.e. having the k highest
phenotypic similarities with pti) to link to it. We experimentally test
the effects of different values of k on the performance of our
proposed algorithm, and we set k=10 as the default value.
Constructing Protein Complex Network
A PPI network (in the bottom level) is an undirected graph
GPPI=(VPPI, EPPI), where VPPI is the set of nodes (proteins) and
E={(u,v)| u,vMVPPI} is the set of edges (protein interactions).
To construct protein complex network in the middle level, we
need to collect known protein complex data or use some
computational methods to predict protein complexes. In this
paper, we use the known protein complex database Compre-
hensive Resource of Mammalian protein complexes
(CORUM) [19], which is a collection of high quality
experimentally verified mammalian protein complexes and
has higher quality than those predicted by computational
methods. However, the CORUM complex database is still far
from complete and it is built from 2400 different genes,
covering 12% of protein-coding genes in human [19]. As such,
our protein complex set COM consists of a set of multi-protein
complexes from CORUM (set CM)a sw e l la sas e to findividual
complexes (set CI) — namely those individual proteins that are
not involved in any of the current CORUM complexes. As
s u c h ,w eh a v et h ef o l l o w i n g :
COM~CM|CI ð2Þ
CM~ cAjcA[CORUM, cA is a complex fg ð 3Þ
CI~ p fg j VcA[CORUM,p= [cA, p[VPPI fg ð4Þ
Given the protein complex set COM, we define the protein
complex network as a directed super graph GCOM=(VCOM, ECOM),
where the super node set VCOM=COM denotes a set of protein
complexes and ECOM={(cA,cB)| cA,cBMVCOM} represents the set of
links between protein complexes. Note that a link (cA,cB)MECOM can
be categorized into one of three types depending on the nature of
complexes cA and cB, namely, EC2C (C2C links between two multi-
protein complexes), EI2I (I2I links between two individual
complexes), and EI2C (I2C links between an individual complex
and a multi-protein complex). Next, we describe how to assign
weight for these three types of links.
Note that each complex cA MCM is a super node that can be
represented as a graph cA=(VcA, EcA)w h e r et h es e tVcA
represents all the proteins in the complex cA,a n dt h es e tEcA
represents the protein-protein interactions among the proteins
in VcA. Given two complexes cA=(VcA, EcA)a n dcB=(VcB, EcB),
cA,cBMCM ,aC2C link EC2C(cA,cB) between cA and cB can be
quantified as follows:
EC2C(cA,cB)~
P
PA[VcA,PB[VcB,PA,PB= [VcA\VcB I(PA,PB)
(jVcAj{jVcA\VcBj)   (jVcBj{jVcA\VcBj)
ð5Þ
where
IP A,PB ðÞ ~
1, if PA,PB ðÞ [EPPI
0, Otherwise
 
ð6Þ
Basically, Equation (5) evaluates how closely the protein members
from different complexes interact with each other overall. It is the
proportion number of interaction between the complexes among
the number of all possible interactions. If there are a lot of physical
interactions between the members from two complexes (non-
overlapping proteins), then the two complexes are likely to be
highly related as mutations of proteins in one of protein complexes
could correspondingly disrupt the other complexes’ functions,
thereby producing similar disease phenotypes. Note that according
to equation (5), it is easy to know that EC2C (cA,cB)=EC2C (cB, cA).
In the case that we have one multi-protein complex cAMCM and
one individual protein complex IA MCI, then the C2I link EC2I (cA, IA)
and the I2C link EI2C (IA, cA) can be defined as follows:
EC2I(cA,IA)~
P
p
A[VcA
I(PA,IA)
jVcAj
,
EI2C(IA,cA)~
P
p
A[VcA
I(PA,IA)
deg(IA)
ð7Þ
Finally, given two individual protein complexes IA and IB,( IA, IB
MCI), then the I2I link EI2I (IA, IB) and the I2I link EI2I (IB, IA) are
computed as follows:
EI2I(IA,IB)~
1
deg(IA)
, EI2I(IB,IA)~
1
deg(IB)
ð8Þ
where deg(IA) is the number of neighbors of vertex IA.
Random walk with restart on the protein complexes
network (RWPCN)
We are now ready to present our proposed algorithm. Given a
query phenotype pti, we aim to prioritize candidate disease genes
based on known disease genes which are associated with pti’s
similar phenotypic neighbors in the phenotype network.
Step 1. Initialization of seed genes and complexes. Let
N(pti) represents the k-NN phenotype neighbor set of the query
phenotype pti where each ptjMN(pti) is similar with pti. Let dis(pti)b e
the set of causative genes of the phenotype pti. We define the seed
disease gene set with respect to pti as S~ |
ptj[N(pti)
dis(ptj).
For a seed disease gene sMS, we assign to it a score
seed(s,pti)~
P
s[dis(ptj)
L(sim(ptj,pti)) [24]. Given a phenotype pti
and the score for its seed gene set seed(s,pti), we can then score
the protein complex cA as follows:
F(cA,pti)~density(cA)  
X
s[VcA
seed(s,pti) ð9Þ
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to pti.
The density of a graph G=(V G,E G), denoted as density (G),
quantifies the richness of edges within G and it is defined as shown
in equation (10) [25]:
density(G)~
2  j EGj
jVGj (jVGj{1)
ð10Þ
Note that 0#density (G)#1. If density (G)=1, then G is a complete
graph, which means every pair of distinct vertices in VG is
connected by an edge. As each protein complex can be viewed as a
graph, we apply density(CA) to quantify the richness of protein
interactions within CA. Those complexes with higher densities and
their component proteins have multiple associations with query
phenotypes and/or their phenotypic neighbors will get higher
scores.
Step 2. Propagating the seeds’ influence to the complexes
in the whole network. We adopt the Random Network
algorithm [26] to the protein complex network. First, the seed
protein complexes are each assigned a score with respect to the
query phenotype if they contain the genes in the seed disease gene
set. We then score all the protein complexes in COM by
propagation. We propose to do flow propagation for this. The
prior disease influence flows of seed complex vertices are
distributed and pumped to their neighbor complexes in the
network. These super vertices will then continue to spread the
influence flows received from previous iteration to their neighbors.
Formally, let F0 be a vector of the initial probabilities of all the
protein complexes in the protein complex network computed using
equation (9). The probability vector at step r, Fr, can be calculated
by equation 11,
Fr~(1{a)W
0
Fr{1zaF0 (r§2) ð11Þ
where F1=F0.
W’ is the column normalized form transpose of adjacency
matrix W which is the transition matrix of the whole protein
complex interaction network. We construct matrix W based on the
three different links between protein complexes. Recall that our
protein complex set COM consists of both multi-protein complexes
(CM) and individual complexes (CI). The matrix W is thus defined
as:
W~
AC2Cn  n ðÞAC2In  m ðÞ
AI2Cm  n ðÞAI2Im  m ðÞ
 !
ð12Þ
where AC2C (n*n), AC2I (n*m), AI2C (m*n) and AI2I (m*m) are the adjacency
sub-matrices. In particular, AC2C (n*n) represents the sub-network
links between multiple-protein complexes (equation 5), AC2I (n*m)
represents the sub-network links from multi-protein complexes to
individual complexes, AI2C (m*n) represents the sub-network links
from individual complexes to multi-protein complexes (equation
7), and AI2I (m*m) represents the sub-network links between
individual protein complexes (equation 8) respectively, where
n=|CM| and m=|C I| are the numbers of multi-protein
complexes and individual complexes respectively.
Note that in Equation 11, the parameter aM(0,1) provides a
probabilistic weighting of spreading the prior information of the
seed complex vertices to other protein complexes at every step. a is
set as 0.8 in our experiments. At the end of the iterations, the prior
information held by every vertex in protein complex network will
reach a steady state which is proven by paper [26]. This is
determined by the probability difference between Fr and Fr-1,
represented as Dif=|Fr2Fr-1| (measured by L1 norm). When
Dif=|Fr2Fr-1|,=10
210, as suggested in Li et al. [3], we consider
that a steady stage has been reached and stop the iterative process.
Note that the function F is smooth over the whole protein
complex-complex network, and each vertex complex is assigned a
value to represent its association with the disease phenotype of
interest.
Step 3. Scoring disease gene based on associations of
protein complexes to diseases. Once the vector Fr reaches a
steady state, we obtain the final scores of protein complexes with
respect to query phenotype. Recall that the final objective of our
algorithm is to prioritize candidate disease genes amongst the
genes in the GPPI. The final step is therefore to prioritize candidate
disease genes based on their associations with protein complexes.
Given a candidate gene g, its association with query phenotype pti,
denoted by S(g, pti), is computed as
S(g,pti)~
X
g[cA
Fr(cA,pti) ð13Þ
where CA is the set of complexes containing the gene g, Fr(cA,p t i)
denotes probability of complex CA associated with phenotype pti
when Fr reaches a steady state. Because mutations on the genes
shared by multiple protein complexes may lead to multiple similar
phenotypes, scores of these shared genes should be the
accumulated score of protein complexes that contain them.
Results
In this section, we firstly introduce the experimental settings and
evaluation metrics. Then, we present the experimental results
compared with state-of-the-art techniques.
Experimental settings and evaluation metrics
Our objective is to uncover novel gene-phenotype relationships.
In order to compare different techniques, we employ standard
leave-one-out cross-validation in our experiments. Each known
gene-phenotype association (g, p) is employed as one test case
where the phenotype p is the query phenotype and the gene g is the
test disease gene. In each round of cross-validation test, we will first
intentionally remove the association (g, p) from our data. We then
run our proposed algorithm to score the genes based on their
associations with protein complexes with respect to the query
phenotype p. If the test disease gene g is ranked as top 1, we will
consider it as a successful prediction; otherwise it is a failed case.
We use the number of overall successful predictions to evaluate the
performance of different prediction methods. Depending on the
genes involved in the ranking, we further categorize our evaluation
metrics into the following two classes, namely, whole genome
evaluation and ab initio evaluation [15]. Whole genome evaluation
proposed by [15] basically ranks all the genes to scan for disease
genes, e.g. we can consider all HPRD genes which do not link to
the query phenotype (exactly same setting with RWRH [3]) and
check how many known test disease genes are still ranked as top 1
in the cross-validation test. However, there are no causative genes
for half of the OMIM phenotypes [4]. Ab initio prediction proposed
by Wu [15] identifies disease genes without any known disease
genes for those query phenotypes. For each phenotype entity, we
remove the gene-phenotype associations from this phenotype p to
all of its known causative genes and we can only use the other
disease genes associated with p’s neighbor phenotypes as the seed
disease gene set. If one of the known causative genes (assuming p is
Disease Gene Prediction on Protein Complex Network
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is ranked top 1, we consider it a successful prediction.
Note in our experiments, the same experimental data and
evaluation metrics have been consistently used to evaluate all the
prediction techniques.
Experimental Results
In this section, we first compare our algorithm with two state-of-
the-art techniques, namely, CIPHER-DN (CIPHER with the
topological distance feature of Direct Neighbors) [15] and RWRH
[3]. Next, we test the sensitivities of the parameters in our proposal
method. For discussion, we present two case studies of predicting
disease genes for two representative diseases i.e., Breast cancer and
Diabetes. Finally, with the computed scores for protein complexes,
we want to validate if those the protein complexes with high scores
are disease related.
Comparison with CIPHER-DN and RWRH. We
compared the performance of our RWPCN algorithm with
current computational techniques, namely, CIPHER-DN and
RWRH, using two evaluation metrics presented above, namely,
whole genome evaluation and ab initio evaluation. Table 1 shows the
overall comparison results of different algorithms. In terms of whole
genome evaluation (second column in Table 1), we observed that
our proposed RWPCN was able to achieve the best result,
successfully predicting 253 genes, which were 8 and 88 more genes
predicted than RWRH and CIPHER-DN respectively. In terms of
ab initio evaluation (third column in Table 1), we were able to
predict 226 disease genes successfully, which were 25 and 69 more
than the RWRH and CIPHER-DN respectively.
Note that in the original CIPHER-DN paper [15], the authors
have adopted a less strict evaluation metric for ab initio evaluation
than ours. As long as the target gene was ranked among the top N
(instead of the top 1), it was regarded as a successful prediction where
N (N.=1) denotes the number of known disease genes for the
query phenotype. Using this less stringent evaluation metric, our
method predicted 240 genes successfully while CIPHER-DN
could only predict 157 genes in the ab initio evaluation.
In the evaluations above, we have used the standard (but old)
gene-phenotype association data which were also used in [3,15] for
comparison purpose. To further validate the predicted associa-
tions, we collected a new version of gene-phenotype association
data extracted from OMIM using BIOMART recently [22]. It
contains 1614 gene-phenotype associations, which includes 274
novel gene-phenotype associations where the disease genes were
unknown in the previous version (other 1340 associations are
shared by both versions). Table 2 shows that using the new gene-
phenotype association data, RWPCN successfully ranked the 273
(a sensitivity of 0.169) genes as top 1 in terms of whole genome
evaluation, and 247 (a sensitivity of 0.153) in terms of ab initio
evaluation, indicating our method is certainly capable of detecting
the novel knowledge which were absent in the older reference
data.
Effect of parameters a and k in RWPCN. Recall that we
have two parameters a and k in our RWPCN algorithm. The flow
parameter a is used in our RWPCN algorithm to control the
proportion of information that flows back into the seed nodes/
protein complexes at each iteration of the algorithm. A larger a
represents that information flows are likely to return to the seed
nodes, therefore those protein complexes near to seed nodes are
more likely to be ranked forward. On the contrary, a smaller a
represents that information flows are likely to flow out of the seed
nodes, therefore those protein complexes near to seed nodes are
more likely to be ranked backward. The second phenotype
parameter k decides the number of related phenotypes with regard
to the query phenotype. An unnecessarily large k will include many
phenotypes which are not relevant while a smaller k will include
lesser number of related phenotypes and may miss out some
important relevant phenotypes as a result.
We first investigated how the flow parameter a affects the
performance of the algorithm. We ran our algorithm with values
of a ranging from 0.2 to 0.9 in steps of 0.1, while keeping the
phenotype k fixed as 10 using leave-one-out cross-validation. The
performance of the algorithms is measured using whole genome
evaluation and ab initio evaluation mentioned above, as shown in
Figure 2.
With increasing value of a, we were able to obtain increased
numbers of successful predictions for both whole genome evaluation
and ab initio evaluation. This is expected since the seed nodes in
protein complex network are more likely to hold the information
flows, thus few flows will be distributed to the distant neighbors in
the network. Biologically, this is reasonable since the protein
complexes (and the corresponding proteins in the complexes) that
directly interact with the disease complexes/proteins are more
likely to be disease/phenotype related. We observe that the
performance of RWPCN with a.=0.4 are better than the
existing CIPHER-DN and RWRH algorithms. In fact, we found
that the optimal values of a can be found within a large range of
0.5,=a,=0.9. As such, selecting a suitable value for a for good
performance is not a problem.
To study the effect of the parameter k that decides the number
of related phenotypes, we ran RWPCN with k f r o m4t o1 5w i t h
a=0.8, based on whole genome and ab initio evaluations. Results
are shown in Figure 3. The performance of RWPCN algorithm
improved with increasing value of k from 4 to 10, indicating that
incorporating more related phenotypes is helpful for prioritizing
target disease genes. However, if we further include more
phenotypes (e.g. when k.10) with low phenotypic similarities,
noisy and un-meaningful phenotypes will be included [23] and
eventually affects the performance of disease gene prediction.
For example, the results in Figures 3 showed that the
Table 1. Overall performance of RWRH, CIPHER-DN and
RWPCN algorithm.
Algorithm Whole genome evaluation Ab initio evaluation
RWPCN 253 226
RWRH 245 201
CIPHER-DN 165 157
We compared RWPCN with RWRH and CIPHER-DN based on the measurement
of whole genome evaluation and ab initio evaluation.
doi:10.1371/journal.pone.0021502.t001
Table 2. Overall performance of BIOMART06, 09 and 06+09
phenotype-gene data.
Phenotype-gene
data
Whole genome
evaluation
Ab initio
evaluation
BIOMART06 253 226
BIOMART09 273 247
BIOMART06+09 285 253
We ran RWPCN on three kinds of phenotype-gene association data, extracted
from BIOMART 06, BIOMART 09 and combination of two version data.
doi:10.1371/journal.pone.0021502.t002
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Nevertheless, the performance of RWPCN algorithm with k in
the wide range [7,12] was consistently better than that of
RWRH and CIPHER-DN, suggesting that RWPCN is insensi-
tive to the specific values of k.
Inferring novel causal genes for breast cancer and
diabetes. We also applied our method for uncovering novel
candidate genes on specific complex genetic diseases. We have
chosen Breast Cancer (MIM: 114480) and Diabetes Mellitus type
2 (MIM: 125853) for our case studies here.
Figure 2. Effect of value a based on whole genome and ab initio evaluation. Figure 2 investigated how the flow parameter affects the
performance of the RWPCN algorithm. With increasing value of a, we can obtain increased numbers of successful predictions for both whole genome
evaluation and ab initio evaluation.
doi:10.1371/journal.pone.0021502.g002
Figure 3. KNN phenotype network on whole genome and ab initio evaluation. This figure studies the effect of the parameter k that decides
the number of related phenotypes. Figure 3 shows the performance of RWPCN algorithm improved with increasing value of k from 4 to 10
(incorporating more related phenotypes) but it performs worse than when k.10 (including low noisy phenotypes). Overall, the performance of
RWPCN algorithm with k in the wide range [7,12] was consistently better than that of RWRH and CIPHER-DN.
doi:10.1371/journal.pone.0021502.g003
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both Breast Cancer and Diabetes Mellitus type 2. Note that we no
longer removed any gene-phenotype associations since our
objective was to predict novel disease genes instead of evaluating
the performance using cross-validation. We ranked the resulting
candidate genes over the whole genome and selected the top 20
ranked genes associating with target phenotypes (Breast Cancer
and Diabetes Mellitus type 2).
The experimental results are listed in Table 3 and 4 for Breast
Cancer and Diabetes Mellitus type 2 respectively.
Table 3 showed 6 highly ranked genes that are also known to
associate with the Breast Cancer. However, we are more interested
in investigating whether our predicted novel susceptible genes are
also associated with disease phenotypes. We searched for
additional gene-phenotype associations from GENECARDS
database [27] and also performed literature search from PubMed
on the other susceptible genes predicted by our algorithm to be
associated to disease phenotype of Breast Cancer (MIM: 114480).
We found 8 additional genes, namely RBBP8, HDAC1, HDAC2,
LMO4, ZNF350, ELAC2, RNASEL and PTEN that are also
reported to be related to Breast Cancer. For CtIP (also known as
retinoblastoma binding protein 8, RBBP8, ranked at 2), the
expression of this gene had been shown to be a novel mechanism
for tamoxifen resistance development in breast cancer [28].
HDAC1 and HDAC2 (ranked at 3 and 4), among class I HDACs,
were reported to regulate the changes in histone acetylation and
were associated with HDAC inhibitors that were expected to
reverse hypoacetylation levels observed even at the early stages of
breast cancer progression [29]. LMO4 (ranked at 6) was a novel
cell cycle regulator with a key role in mediator of ErbB2/HER2/
HER2/Neu-induced breast cancer cell cycle progression [30].
Genetic variants and haplotype analyses of the ZNF350 (ranked at
12) gene suggested that it is associated with high-risk non BRCA1/
2 French Canadian breast and ovarian cancer families [31].
Germline mutation in RNASEL (ranked at 15) predicted increased
risk of breast cancer [32]. Finally, Tsou HC et al. [33] reported
three novel MMAC1/PTEN (ranked at 16) mutations in CS
(Cowden syndrome) were associated with breast cancer. All these
showed that our prediction method could discover novel disease
genes for breast cancer beyond the original disease gene set.
Table 4 showed our prediction results for Diabetes Mellitus
type 2. Out of the top 20 predicted disease genes, 8 genes were
known to associate with the phenotype. We found three
additional genes PIK3R1, EP300 and ABCC8 also related to
the disease phenotypes. PIK3R1 (ranked at 1) had been tested
for their influence on insulin action, showing significant
associations with diabetes [34]. EP300 (ranked at 13, aliases
p300), as a transcriptional coactivator, could cause diabetes via
regulating fibronectin expression via PARP and NF-kappaB
activation [35]. For ABCC8, a rare mutation in ABCC8/SUR1
(ranked at 20) had been reported to have an effect on K(ATP)
channel activity and beta-cell glucose sensing, leading to diabetes
in adulthood [36].
From Tables 2 and 3, we found our predicted disease genes
indeed mapped significantly with disease genes that were either
curated in existing databases or reported in the literature. This
suggests that the other unmatched ones could be potentially real
disease genes that are worth being further validated by clinicians
and biologists.
Table 3. Breast cancer genes prediction.
Rank Score HGNC Gene symbol Mark
1 3.61665 BRCA1 *
2 2.64458 RBBP8 !
3 1.04115 HDAC1 !
4 1.02108 HDAC2 !
5 1.00632 CTBP1 ,
6 0.983392 LMO4 !
7 0.814445 RAD51 *
8 0.812762 BRCA2 *
9 0.807072 NBN *
10 0.806886 BRIP1 *
11 0.801356 PIK3CA *
12 0.671104 ZNF350 !
13 0.142519 SMAD3 ,
14 0.141945 ELAC2 !
15 0.141729 RNASEL !
16 0.140748 PTEN !
17 0.0947266 TP53 ,
18 0.0849672 SMAD4 ,
19 0.0831955 EP300 ,
20 0.0721527 CREBBP ,
Genes marked with * are known disease genes associated with Breast Cancer
(MIM: 114480), genes marked with ! are the genes associated with Breast
Cancer (MIM: 114480) either extracted from literature or from GENECARDS
database, genes marked with , are un-related to disease.
doi:10.1371/journal.pone.0021502.t003
Table 4. Diabetes genes prediction.
rank Score HGNC Gene symbol Mark
1 1.34591 PIK3R1 !
2 1.33691 IRS1 *
3 1.33691 INSR *
4 1.33691 KHDRBS1 ,
5 0.821847 NEUROD1 *
6 0.812877 IPF1 *
7 0.810154 SLC2A4 *
8 0.802705 MAPK8IP1 *
9 0.802453 TCF2 *
10 0.802404 PPP1R3A *
11 0.354724 TCF1 ,
12 0.194629 CREBBP ,
13 0.15557 EP300 !
14 0.102423 PCAF ,
15 0.0807789 PLN ,
16 0.0806853 RPS6KA1 ,
17 0.0652625 CUL3 ,
18 0.0652625 SPOP ,
19 0.0595811 POLR2A ,
20 0.0471911 ABCC8 !
Similarly, Genes marked with * are known disease genes associated with
Diabetes Mellitus, type 2 (MIM: 125853), genes marked with ! are the genes
associated with Diabetes Mellitus, type 2 (MIM: 125853), extracted from
literature or from GENECARDS database, genes marked with , are un-related
with disease.
doi:10.1371/journal.pone.0021502.t004
Disease Gene Prediction on Protein Complex Network
PLoS ONE | www.plosone.org 8 July 2011 | Volume 6 | Issue 7 | e21502Detecting disease-related protein complexes. Recall that
we have assigned scores to the protein complexes to indicate the
degree of association of the protein complexes to the query disease
phenotypes. The higher the scores protein complexes were
assigned, the higher probability protein complexes were
associated with corresponding phenotypes. Based on the scores,
we ranked the protein complexes and studied the two top-ranked
complexes here: Sarcoglycan-sarcospan complex (SG-SPN) and
Pex26-Pex6-Pex1 complex. For evaluation, a set of 248 disease
protein complexes from Lage et al. [18] was used as our
benchmark.
Figure 4 showed that the SG-SPN complex (surrounded by green
line) contained five human proteins: Q16586, Q16585, Q92629,
Q13326, Q14714 and it was ranked at top 1 protein complex in
predicting phenotype (MIM: 608099)-gene (SGCA) association by
our RWPCN algorithm. We found that this SG-SPN complex had
a large overlap (shared four proteins) with the disease complex
No. 230 (surrounded by red dash line) in our benchmark set. We
also found that all shared 4 proteins were known disease genes
linked to phenotypes (Blue dash links), which had high phenotypic
similarities among them. Noted that gene Q14714 (SSPN) in SG-
SPN complex was associated with phenotype Fukuyama Congen-
ital Muscular Dystrophy (FCMD) (MIM: 253800) [37] which was
closely related to phenotype (MIM: 608099) in our phenotype
network, indicating that SG-SPN complex could indeed be a valid
disease complex.
Similarly, Figure 5 showed the Pex26-Pex6-Pex1 complex
(surrounded by green line) which covered a benchmark disease
complex (surrounded by red dash line) that consisted of proteins
O43933 (PEX 1) and Q13608 (PEX 6). This complex was
ranked at top 1 in inferring phenotype (MIM: 202370)-gene
(PEX26) association. The Pex26-Pex6-Pex1 complex was
involved in peroxisome biogenesis disorders (PBDs), which
included the Zellweger syndrome spectrum (PBD-ZSD)a n d
rhizomelic chondrodysplasia punctata type 1 (RCDP1). PBD-
ZSD represented a continuum of disorders including infantile
Refsum disease (MIM: 266510), neonatal adrenoleukodystrophy
(MIM: 202370), and Zellweger syndrome (MIM: 214100). Noted
that the Q7Z412 (PEX 26) protein in the our predicted disease
complex was also a known disease gene associated with all the
three phenotypes, suggesting that the mutations of proteins in the
same CORUM protein complexes were likely to induce the same
or similar phenotypes. It also showed that our highly ranked
protein complexes were indeed disease related.
Discussion
While great progress has been made in genomics and
proteomics, discovering the associations between genes and
phenotypes have remained challenging. In this paper, we
constructed a novel human protein complex network by
integrating HPRD protein interaction network [20] and CORUM
protein complexes [19]. We showed that a genome-wide disease
gene prioritization for multi-factorial diseases can be obtained
using such a human protein complex network. Using our method,
the top ranked candidate disease genes that are found to be closely
associating with protein complex can potentially be used to guide
the prediction of disease-related protein complexes.
We have verified the ability of our RWPCN algorithm to
disclose gene-phenotype associations through extensive experi-
ments. We first exploit known gene-phenotype associations to
initialize the higher-level complex phenotype associations based on
the modular nature of complex diseases. Then, we prioritize
candidate disease genes for disease phenotypes using the network
propagation technique on the complex interaction network. Our
RWPCN algorithm was shown to outperform the existing methods
RWRH [3] and CIPHER [15] which only use gene/protein level
associations. This suggests that our protein complex network can
Figure 4. SG-SPN overlaps with the disease complex No. 230. Figure 4 showed that the SG-SPN complex (surrounded by green line)
contained five human proteins. We found that this SG-SPN complex had a large overlap (shared four proteins) with the disease complex No. 230
(surrounded by red dash line) in our benchmark set. We also found that all shared 4 proteins were known disease genes linked to phenotypes (Blue
dash links), which had high phenotypic similarities among them. Gene Q14714 (SSPN) in SG-SPN complex was associated with phenotype Fukuyama
Congenital Muscular Dystrophy (FCMD) (MIM: 253800) [37] which was closely related to phenotype (MIM: 608099) in our phenotype network.
doi:10.1371/journal.pone.0021502.g004
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interaction networks better than simple protein interaction
networks, as it is a more effective basis for interrogating the
human phenome-interactome network for gene-phenotype asso-
ciations through our RWPCN algorithm.
It should be acknowledged that the proposed RWPCN
algorithm can be improved further. As RWPCN relies on the
human protein complex interaction network, the coverage of the
protein complex data can affect the performance of prediction.
Since the current protein complex data is by no means complete,
predicted human protein complexes with high quality could be
taken into consideration. Combining the predicted and experi-
mental validated complex data into the prioritization process (e.g.
using the method reviewed in [38–40]), could increase the power
of prediction as long as we also ensure the quality of the complex
data. RWPCN also depends on the quality (i.e. reliability) of the
PPI data in the current model, and it may be more suited to
certain kind of diseases than others. It is well-known that PPI data
generated with high-throughput methods can be of inferior
quality. One possible improvement is to weight protein-protein
interactions using diverse biological evidences (e.g. protein
sequences, domain, motif, topological properties of PPI network
[41,42], protein localization, molecular function, biological
process and gene expression profiles [43,44], metabolic reactions
[45], etc) to improve the reliability of the PPI data that we use for
disease gene prioritization. We are currently exploring these and
other approaches to further improve our RWPCN algorithm for
discovering gene-phenotype associations.
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